Epidemiology of Antiphospholipid Syndrome in the General Population

Curr Rheumatol Rep. 2022 Jan 5;23(12):85. doi: 10.1007/s11926-021-01038-2.


Purpose of review: The epidemiology of antiphospholipid syndrome (APS) is poorly understood. Here, we review the current understanding of the epidemiology of antiphospholipid syndrome in the general population and the frequency of antiphospholipid antibodies in the general population in patients with obstetric morbidity, arterial events, and venous thromboembolism.

Recent findings: There have been few population-based studies that estimated the prevalence and incidence of APS. The estimated incidence and prevalence among most these studies ranged between 1 and 2 cases per 100,000 and 40 and 50 cases per 100,000 respectively. The prevalence of antiphospholipid antibodies in patients with obstetric morbidity was 6-9%, while in arterial events and venous thromboembolism is 9-10%. However, this data remains limited. Mortality of patients with APS is 50-80% higher than the general population. The epidemiology of APS has been difficult to elucidate. Population-based studies patients with diverse age, racial, and ethnic backgrounds are needed.

Keywords: Antiphospholipid syndrome; Epidemiology.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid
  • Antiphospholipid Syndrome* / epidemiology
  • Female
  • Humans
  • Incidence
  • Pregnancy
  • Prevalence


  • Antibodies, Antiphospholipid